Skip to main content
 Home > Surrogacy Knowledge >

Test tube baby's first share rose three times in a row, and Blue City brothers concealed overseas surrogacy services

2022-09-13 11:22 browse:

Original title: the first share of test tube baby has risen for three consecutive times

Blue City brothers has hidden overseas surrogacy services

AI financial news agency, Tang Yu, editor of zhaoyanqiu

Although Zheng Shuang's choice of surrogacy is expressly prohibited in China, assisted reproductive technologies such as test tube baby are a "broad money market" in China, and the capital has already been laid out

According to the updated statistics in 2020, there are a total of 12 assisted reproduction concept listed institutions in China's A-share market, of which 3 stocks are traded on the Shanghai Stock Exchange and the other 9 on the Shenzhen Stock Exchange

In Hong Kong stocks, there is Jinxin reproduction

Three days after the Zheng Shuang event, related concept stocks rose partially on January 20

Only Longtou Jinxin reproduction has continued to rise in recent days

Before the news broke on January 18, Jinxin reproductive had fallen sharply for 7 consecutive days, but then its share price hit the bottom and rebounded, rising for three consecutive days

As of press time, the market value of Jinxin reproductive has reached HK $38billion, closing at 15

HK $74, up 3

01%。 "Although surrogacy is illegal, test tube babies are legal, which is good for Jinxin reproduction, an institution that treats infertility

" A person who has been focusing on the Hong Kong stock market for a long time said that Jinxin reproduction is a scarce target in the secondary market, and it will be very hot in 2019

Compared with Changchun hi tech and Lizhu group, which are just upstream and downstream of the industrial chain, Jinxin reproductive, which landed in the Hong Kong Stock Exchange in 2019, is the first share of the real "test tube baby", and the third-generation test tube baby service revenue accounts for 86% of Jinxin reproductive

9%。 The 2019 financial report shows that Jinxin reproductive sales revenue is about 16

RMB 500million, a year-on-year increase of 78

8%, and the net profit is about 4

RMB 200million, a year-on-year increase of 98

3%。 Jinxin reproduction originated in 2003

The doctor team and management personnel established Jinjiang reproduction center (non-profit hospital) in Chengdu, Sichuan

The team later joined Jinxin group

Subsequently, Jinxin reproductive expanded its territory all the way from Sichuan to South China by acquiring two hospitals

In December, 2018, the institution acquired hrcmanagement, which manages nine California clinics, and made its business abroad

In 2020, Jinxin spent another 30million US dollars to establish a joint venture in the Cayman Islands with Mengmei, a well-known intermediary agency to give birth to children in the United States, to develop its main business

In China, the licenses of assisted reproduction are strictly regulated by the government, 90% of which are concentrated in public hospitals

One advantage of Jinxin reproduction is that it has licenses from China and the United States

According to frost&sullivan, the prevalence of infertility in China is expected to increase from 16% in 2018

0% to 18% in 2023

2%。 The huge demand has attracted a large number of listed institutions

A number of listed institutions, including Fosun medicine, Tongce medical, Yuexin health and McGrady technology, are also participating in the field of assisted reproduction

In january2019, McGrady technology acquired more than 50% of the shares of Haikou Mary Hospital, officially entering the assisted reproduction track

With the approval of the Family Planning Commission, Haikou Mary Hospital has been carrying out artificial insemination (AIH), in vitro fertilization embryo transfer (IVF-ET) and intracytoplasmic sperm injection (ICSI) since 2016

The business of assisted reproduction is aimed not only at infertile couples, but also at single women, LGBT groups (lesbians, gays, bisexuals and transgenders)

In 2020, Blue City brothers, which landed in the US stock market, also has related surrogacy services on its multi population dating software bull

On the app, this service is called familyplanningservices (family planning services)

The introduction is to "provide professional consulting services for users seeking overseas assisted reproductive health care"

Individual overseas cases are displayed in the album

Previously, according to media reports, surrogacy quotes can even be directly generated in the app

In 2017, Blue City brothers launched the "blue baby" service

That same year, Geng Le, the founder of blued, got a child through surrogacy in the United States

In 2019, the business income of "blue baby" was about 9

21 million yuan, accounting for 1% of the total income

2%。 In 2020, Q1 revenue reached 4

13 million yuan, accounting for about 2% of the total revenue, but Q3 did not disclose it in detail

In addition to "blue baby", in 2018, Blue City brothers also spent 20

6 million yuan to acquire the intermediary "Mengmei life" 8

15% of the shares, the purpose of which is to "expand their own family planning business"

In China, where surrogacy is forbidden, this service is controversial

Since 2020, this service in app has experienced many twists and turns from off the shelf to on the shelf to off the shelf

AI financial news agency found that the official website of "blue baby" can no longer be opened and is displayed in the system upgrade

This article was originally produced by AI finance and economics, an account of Caijing Tianxia weekly

Please do not reprint it on any channel or platform without permission

Violators will be prosecuted

Responsible editor: